NCT00040248View on ClinicalTrials.gov

Daclizumab to Treat Wegener's Granulomatosis

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 30, 2002

Study Completion Date

May 31, 2005

Conditions
Wegener's Granulomatosis
Interventions
DRUG

Daclizumab

Trial Locations (1)

20892

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00040248 - Daclizumab to Treat Wegener's Granulomatosis | Biotech Hunter | Biotech Hunter